Literature DB >> 1457192

HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA.

A G Bukrinskaya1, G K Vorkunova.   

Abstract

We have shown previously that HIV-1 matrix protein p17 is transported to the nucleus of Jurkat-tat and H9 cells soon after infection. As shown in this combination, gag polyprotein p55 synthesized 48 h after cell infection is cleaved in cytosol rapidly after its synthesis, and nascent p17 enters the nuclei and gradually accumulates there. Uncleaved p55 molecules and intermediate precursors are rapidly transported to the membranes and are also found in nuclei. Mature gag proteins are seen in membranes only after prolonged period of labelling or chase (4 or more hours later). To determine whether the nascent p17 is associated with viral genomic RNA in the nuclei, the cells were fractionated, the viral complexes were immunoprecipitated by monoclonal antibodies (MAbs) against gag proteins, and RNA was extracted and analyzed by slot and blot hybridization. MAb against p17 precipitated all the viral RNA from the nuclei including full-size genomic RNA and essential parts from membranes while MAb against p24 did not precipitate any viral RNA from the nuclei. These data suggest that matrix protein is linked to genomic RNA in the nuclei and raise the possibility that p17 may transfer viral nucleocapsids from the nuclei to plasma membranes, the site of virus assembly.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457192     DOI: 10.1089/aid.1992.8.1795

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  12 in total

1.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

2.  Molecular factors required for human immunodeficiency virus type I infectivity.

Authors:  A G Bukrinskaya; G K Vorkunova; M E Burshteĭn; T V Gorodnicheva; M Stevenson
Journal:  Dokl Biol Sci       Date:  2005 Jul-Aug

3.  The matrix protein of human immunodeficiency virus is cleaved and packed into virion cores.

Authors:  A G Bukrinskaya; G K Vorkunova; M E Burshtein; M Stevenson
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

4.  Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.

Authors:  W Zhou; M D Resh
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Functional characterization of the human immunodeficiency virus type 1 genome by genetic footprinting.

Authors:  L C Laurent; M N Olsen; R A Crowley; H Savilahti; P O Brown
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.

Authors:  E O Freed; J M Orenstein; A J Buckler-White; M A Martin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells.

Authors:  N Chazal; C Carrière; B Gay; P Boulanger
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.

Authors:  Tao Wang; Wenyan Zhang; Chunjuan Tian; Bindong Liu; Yunkai Yu; Lingmei Ding; Paul Spearman; Xiao-Fang Yu
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

9.  Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein.

Authors:  L J Parent; C B Wilson; M D Resh; J W Wills
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway.

Authors:  N Chazal; B Gay; C Carrière; J Tournier; P Boulanger
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.